LATEST NEWS
Health as a human right, cancer care as a human priority
Universal health coverage in oncology is still not a reality, as a recent report shows
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
HIGHLIGHTS FROM ELCC2024
Could subcutaneous administration become the standard for immunotherapy?
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability
A study shows correlation between fatty acids intake and response to immunotherapy
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
Promising efficacy data reported for a targeted agent harbouring a MET alteration in NSCLC
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
ROAD TO ESMO GASTROINTESTINAL CANCERS CONGRESS 2024
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Colorectal cancer screening: performance of a blood-based test is promising
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma